EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retro-2 Enhances Tumor-Cell MHC-I Antigen Presentation and CD8+ T Cell-Dependent Antitumor Immunity

Zhuo-Shuo Xu, Xuan-Ang Zhou, Qian Zhang, Kai Jiang, Zi-Lun Ruan, Ming-Ming Hu

International Journal of Molecular Sciences · 20.11.2026 · 27 (22) · 10449

DOI: 10.3390/ijms272210449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.11.2026. Verfasst von Zhuo-Shuo Xu und 5 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Key R&D Program of China, Fundamental Research Funds for the Central Universities, Natural Science Foundation Exploration Program (Morning Light Program) of Wuhan City.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Defective major histocompatibility complex class I (MHC-I) antigen presentation enables tumor immune evasion and limits programmed cell death protein 1 (PD-1) blockade efficacy. We tested whether pharmacological enhancement of tumor-cell MHC-I presentation could restore immunogenicity and sensitize tumors to checkpoint therapy. Retro-2, a cyclic inhibitor of retrograde toxin trafficking, increased MHC-I transcripts, surface MHC-I/HLA-ABC, and peptide–MHC-I presentation in murine B16-F10 melanoma and Panc02 pancreatic cancer cells and in human A375 melanoma and BxPC-3 pancreatic cancer cells. These changes enhanced antigen-specific CD8+ T cell killing and IFN-γ/TNF-α release, and increased human tumor-cell susceptibility to tumor-lysate-primed CD8+ T cells. In syngeneic mouse models of B16-F10 melanoma and Panc02 pancreatic cancer, Retro-2 delayed tumor growth, reduced tumor burden, and prolonged survival, accompanied by increased intratumoral CD8+ T cell abundance, proliferation, effector function, and progenitor-exhausted cells. CD8+ T cell depletion largely abolished Retro-2 activity. Combining Retro-2 with PD-1 blockade produced greater tumor control than either monotherapy in both models. Retro-2 was well tolerated, with no detectable changes in body weight, hematological indices, or major-organ histology. These findings identify Retro-2 as a pharmacological enhancer of tumor MHC-I presentation that promotes CD8+ T cell-dependent antitumor immunity and improves PD-1 blockade efficacy.

Förderung

  • State Key R&D Program of China
  • Fundamental Research Funds for the Central Universities
  • Natural Science Foundation Exploration Program (Morning Light Program) of Wuhan City

Zitieren

APA

Xu, Z., Zhou, X., Zhang, Q., Jiang, K., Ruan, Z., & Hu, M. (2026). Retro-2 Enhances Tumor-Cell MHC-I Antigen Presentation and CD8+ T Cell-Dependent Antitumor Immunity. International Journal of Molecular Sciences, 27(22), 10449. https://doi.org/10.3390/ijms272210449

Vancouver

Xu Z, Zhou X, Zhang Q, Jiang K, Ruan Z, Hu M. Retro-2 Enhances Tumor-Cell MHC-I Antigen Presentation and CD8+ T Cell-Dependent Antitumor Immunity. International Journal of Molecular Sciences. 2026;27(22):10449. doi:10.3390/ijms272210449

BibTeX
@article{Xu2026,
  author = {Xu, Zhuo-Shuo and Zhou, Xuan-Ang and Zhang, Qian and Jiang, Kai and Ruan, Zi-Lun and Hu, Ming-Ming},
  title = {Retro-2 Enhances Tumor-Cell MHC-I Antigen Presentation and CD8+ T Cell-Dependent Antitumor Immunity},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10449},
  doi = {10.3390/ijms272210449}
}
Kostenlos starten →